Journal of Antimicrobial Chemotherapy (1993) 31, 523-532
© 1993 The British Society for Antimicrobial Chemotherapy
other |
In-vitro susceptibilities of Pseudomonas aeruginosa and Pseudomonas spp. to the new fluoroquinolones clinafloxacin and PD 131628 and nine other antimicrobial agents
Infectious Disease Section, Departments of Medicine and Pharmacology, Stratton VA Medical Center and Albany Medical College Albany, New York 12208, USA
Received 1 June 1992; accepted 21 November 1992
*Corresponding author
The in-vitro activities of two new fluoroquinolones, clinafloxacin (CI-960, PD 127391, AM-1091) and PD 131628 (the active component of the pro-drug CI-990, PD 131112) and nine other antibiotics were tested against 107 clinical isolates of Pseudomonas aeruginosa. 12 isolates of Xanthomonas maltophilia. and 19 isolates of other Pseudomonas spp. Of the 107 P. aeruginosa isolates, 33 were resistant to gentamicin, tobramycin and amikacin, 17 were resistant to only one or two of these aminoglycosides and 24 were aminoglycoside sensitive. Thirty-three were isolates from cystic fibrosis patients. Susceptibility studies were performed using the agar dilution technique and kinetic time kill curves. With the exception of aminoglycoside-sensitive P. aeruginosa isolates where ciprofloxacin had similar activity to cinafloxacin and PD 131628, the two new fluoroquinolones were the most active agents against all isolates tested (MIC90 0·25–2·0 mg/L). Cross-resistance was identified with ciprofloxacin and ofloxacin-resistant strains, but the superior activity of clinafloxacin and PD 131628 resulted in 90% of the isolates having MICs < 2 mg/L. Kinetic kill curves with aminoglycoside-sensitive P. aeruginosa revealed ciprofloxacin to have the most rapid and sustained killing. However, with amino glycoside-resistant P. aeruginosa isolates, clinafloxacin and PD 131628 were more rapidly bactericidal than ciprofloxacin.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. Zhang, J. Parente, S. M. Harris, D. E. Woods, R. E. W. Hancock, and T. J. Falla Antimicrobial Peptide Therapeutics for Cystic Fibrosis Antimicrob. Agents Chemother., July 1, 2005; 49(7): 2921 - 2927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Siami, N. Christou, I. Eiseman, K. J. Tack, and the Clinafloxacin Severe Skin And Soft Tissue Infe Clinafloxacin versus Piperacillin-Tazobactam in Treatment of Patients with Severe Skin and Soft Tissue Infections Antimicrob. Agents Chemother., February 1, 2001; 45(2): 525 - 531. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. Weiss, C. Restieri, E. De Carolis, M. Laverdiere, and H. Guay Comparative activity of new quinolones against 326 clinical isolates of Stenotrophomonas maltophilia J. Antimicrob. Chemother., March 1, 2000; 45(3): 363 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Clark, M. R. Jacobs, and P. C. Appelbaum Activities of Clinafloxacin, Alone and in Combination with Other Compounds, against 45 Gram-Positive and -Negative Organisms for Which Clinafloxacin MICs Are High Antimicrob. Agents Chemother., September 1, 1999; 43(9): 2295 - 2298. [Abstract] [Full Text]
|
|
|
|
|
|
L. M. Ednie, M. R. Jacobs, and P. C. Appelbaum Comparative Activities of Clinafloxacin against Gram-Positive and -Negative Bacteria Antimicrob. Agents Chemother., May 1, 1998; 42(5): 1269 - 1273. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Denton and K. G. Kerr Microbiological and Clinical Aspects of Infection Associated with Stenotrophomonas maltophilia Clin. Microbiol. Rev., January 1, 1998; 11(1): 57 - 80. [Abstract] [Full Text] [PDF]
|
|